
If you're a member: Log-in to get more information about this trial.
A randomized phase III trial of trastuzumab + ALpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously treated HER2+ Advanced BrEasT cancer.
ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland
Contact
Phone: +41 31 511 94 00
E-mail: contact@etop.ibcsg.org